O
OcuMension Therapeutics
Company which focuses on the development of ophthalmic medications
About OcuMension Therapeutics
Ocumension Therapeutics specializes in developing and commercializing innovative ophthalmic solutions aimed at enhancing eye health. The company operates in the pharmaceutical sector, focusing on the treatment of eye diseases and conditions. Ocumension serves a diverse range of clients, including healthcare providers, hospitals, and clinics, primarily in the Asia-Pacific region. The business model revolves around research and development, clinical trials, and the subsequent commercialization of its products. Revenue is generated through the sale of its therapeutic products and potential licensing agreements with other pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2017
- Headquarters
- Huangpu, China
- Listing
- IPO 2020
- Employees
- 23
- Open positions
- None listed
- Dealroom signal
- 35.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Ophthalmology, Drug Development, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 2 companies, latest Apr 2021
- Capital deployed
- —
- Preferred round
- POST IPO EQUITY
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Oct 2024 | $0 | — | Alcon | ↗ |
| IPOOther financing | Jul 2020 | $184M | $184M | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $152M | +37.4% | $16M | 10.3% |
| 2025 | $111M | +92.7% | −$2M | -1.9% |
| 2024 | $57M | +69.4% | −$24M | -42.1% |
| 2023 | $34M | +55% | −$45M | -131.8% |
| 2022 | $22M | +183.1% | −$49M | -224.4% |
| 2021 | $7.7M | +328.7% | −$51M | -661.3% |
| 2020 | $1.8M | — | −$312M | -17316.6% |
Growth signals
Latest recorded traffic for OcuMension Therapeutics is 390 monthly website visits, up 34.5% over the last three months. OcuMension Therapeutics's team declined 11.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Alimera SciencesAlpharetta, United StatesDevelops and commercializes prescription ophthalmic pharmaceuticals
$360Mvaluation
EyePoint PharmaceuticalsWatertown, United StatesTiny, sustained-release drug delivery products designed to deliver drugs at a controlled and steady rate
$233Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later1 investor entered at this stage
Alcon
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about OcuMension Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OcuMension Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.